Aortic valve disease 2 is an autosomal dominant, variably expressive SMAD6-associated congenital left-sided cardiovascular malformation spectrum centered on bicuspid aortic valve and often accompanied by aortic stenosis, coarctation, thoracic aortic aneurysm, and early valve or aortic calcification. The mechanistic core is reduced SMAD6-mediated inhibition of BMP and related TGF-beta signaling during endocardial cushion and outflow tract development, with a later fibrocalcific valvulo-aortic phase in susceptible individuals.
Ask a research question about Aortic Valve Disease 2. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Aortic Valve Disease 2
creation_date: "2026-03-26T20:45:00Z"
updated_date: "2026-04-26T22:37:19Z"
category: Mendelian
description: >-
Aortic valve disease 2 is an autosomal dominant, variably expressive
SMAD6-associated congenital left-sided cardiovascular malformation spectrum
centered on bicuspid aortic valve and often accompanied by aortic stenosis,
coarctation, thoracic aortic aneurysm, and early valve or aortic
calcification. The mechanistic core is reduced SMAD6-mediated inhibition of
BMP and related TGF-beta signaling during endocardial cushion and outflow
tract development, with a later fibrocalcific valvulo-aortic phase in
susceptible individuals.
definitions:
- name: Clinical disease framing for aortic valve disease 2
definition_type: CASE_DEFINITION
description: >-
Aortic valve disease 2 is a congenital SMAD6-associated valvulo-aortic
disorder defined by bicuspid aortic valve with associated left-sided
outflow-tract malformations and/or thoracic aortopathy.
scope: Gene-focused framing of the cardiovascular branch of SMAD6 deficiency
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In conclusion, we report a significant contribution of SMAD6 mutations to
the etiology of the BAV/TAA phenotype.
explanation: >-
This large cohort study directly supports a SMAD6-associated bicuspid
aortic valve and thoracic aortic aneurysm disease entity.
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We conclude that low-frequency deleterious variants in SMAD6 predispose to CVM.
explanation: >-
This landmark report establishes the cardiovascular malformation branch of
SMAD6-related disease.
- name: Molecular definition for aortic valve disease 2
definition_type: DIAGNOSTIC_CRITERIA
description: >-
Molecularly, this entry captures heterozygous deleterious SMAD6 variants
that impair inhibitory control of BMP signaling in bicuspid aortic valve
and related aortopathy.
scope: Molecular anchoring of the cardiovascular branch of SMAD6-related disease
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SMAD6 was identified as the most important known gene in the etiology of
BAV with associated TAA.
explanation: >-
This supports using SMAD6 as the molecular anchor of the bicuspid
valve-thoracic aortopathy branch.
disease_term:
preferred_term: aortic valve disease 2
term:
id: MONDO:0013902
label: aortic valve disease 2
synonyms:
- SMAD6-related aortic valve disease
- SMAD6-related BAV/TAA
categories:
- Congenital Heart Disease
- Valvuloaortopathy
- Developmental Cardiovascular Disorder
mappings:
mondo_mappings:
- term:
id: MONDO:0013902
label: aortic valve disease 2
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: Primary MONDO disease identifier for the SMAD6 cardiovascular branch.
external_assertions:
- name: ClinGen SMAD6 gene-disease validity assertion
source: ClinGen
assertion_type: gene_disease_validity_lumped_assertion
external_id: CCID:009009
url: https://search.clinicalgenome.org/CCID:009009
description: >-
ClinGen curated SMAD6 under a lumped disease entity anchored to syndromic
craniosynostosis, incorporating aortic valve disease 2, craniosynostosis 7,
and radioulnar synostosis.
notes: >-
This external assertion is broader than the present entry, which
intentionally isolates the cardiovascular pathophysiology branch for
dismech.
evidence:
- reference: PMID:36414630
reference_title: SMAD6-deficiency in human genetic disorders.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SMAD6 encodes an intracellular inhibitor of the bone morphogenetic protein
(BMP) signalling pathway.
explanation: >-
Companion review supporting the lumped SMAD6 gene-disease validity context
that ClinGen curates and that this entry isolates a cardiovascular branch
of.
inheritance:
- name: Autosomal dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
penetrance: INCOMPLETE
expressivity: VARIABLE
description: >-
Familial bicuspid aortic valve with associated thoracic aortopathy usually
follows an autosomal dominant pattern but with reduced penetrance and broad
clinical variability. Apparently unaffected relatives can carry SMAD6
variants or develop later thoracic aortopathy, so family screening and
longitudinal interpretation are clinically important.
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Transmission of BAV/TAA mostly complies with an autosomal dominant inheritance
pattern, displaying reduced penetrance and variable expressivity
explanation: >-
This cohort review explicitly supports autosomal dominant inheritance with
incomplete penetrance and variable expressivity in the SMAD6-associated
bicuspid valve-aortopathy phenotype.
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The mutation was also observed in an unaffected daughter (age 28) of the
proband (Supplementary Figure 1).
explanation: >-
This directly supports the unaffected-carrier nuance that drives family
screening and longitudinal counseling.
progression:
- phase: Congenital valve and outflow tract morphogenesis phase
age_range: embryogenesis to birth
notes: >-
Reduced SMAD6 function perturbs endocardial cushion transformation and
outflow tract development, producing congenital valve and great-vessel
malformations.
evidence:
- reference: PMID:10655064
reference_title: A role for smad6 in development and homeostasis of the cardiovascular system.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Hyperplasia of the cardiac valves and outflow tract septation defects
indicate a function for Smad6 in the regulation of endocardial cushion
transformation.
explanation: >-
Mouse data support an early developmental morphogenesis phase downstream
of Smad6 loss.
- phase: Postnatal fibrocalcific valvulo-aortic phase
age_range: childhood through adulthood
notes: >-
Congenital bicuspid architecture can progress to stenosis, calcification,
coarctation-associated disease, and thoracic aortic aneurysm over time.
evidence:
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In conclusion, we identified a novel SMAD6 variant causing a severely
calcified BAV and TAA, which contributes to our understanding of the
clinical and genetic background of SMAD6-related BAV.
explanation: >-
This case report supports a later fibrocalcific and aneurysmal disease
phase in SMAD6-related bicuspid aortic valve disease.
pathophysiology:
- name: Germline SMAD6 loss with impaired BMP/TGF-beta restraint
description: >-
Heterozygous deleterious SMAD6 variants reduce inhibitory control of BMP
signaling, with related effects on TGF-beta pathway crosstalk, establishing
the shared upstream lesion of the cardiovascular branch.
gene:
preferred_term: SMAD6
modifier: DECREASED
term:
id: hgnc:6772
label: SMAD6
downstream:
- target: Endocardial cushion and outflow tract morphogenesis defects
description: Excess developmental signaling perturbs valve and outflow tract patterning.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- dysregulated BMP/TGF-beta signaling
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Overall, these results imply that mutations in SMAD6 likely cause BAV/TAA
through impaired negative regulation of BMP and/or TGF-β signaling.
explanation: >-
This directly supports the causal edge from SMAD6 loss to dysregulated
developmental signaling in the valve-aortic phenotype.
evidence:
- reference: PMID:36414630
reference_title: SMAD6-deficiency in human genetic disorders.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SMAD6 encodes an intracellular inhibitor of the bone morphogenetic protein
(BMP) signalling pathway.
explanation: >-
This review defines the shared upstream molecular role of SMAD6 as an
intracellular BMP inhibitor.
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SMAD6 encodes an inhibitory SMAD protein which negatively regulates BMP
signaling by binding to BMP type I receptors or by establishing competitive
interactions for SMAD4 (Imamura et al., 1997; Hata et al., 1998).
explanation: >-
This provides direct disease-relevant evidence that SMAD6 restrains BMP
signaling in the bicuspid valve-thoracic aneurysm context.
- name: Endocardial cushion and outflow tract morphogenesis defects
description: >-
Loss of SMAD6-mediated signaling control perturbs endocardial cushion
transformation, outflow tract septation, and related cardiac neural
crest/mesenchymal developmental programs.
downstream:
- target: Congenital bicuspid valve and left-sided outflow phenotype
description: Developmental morphogenesis defects produce bicuspid aortic valve and related left-sided malformations.
causal_link_type: DIRECT
evidence:
- reference: PMID:10655064
reference_title: A role for smad6 in development and homeostasis of the cardiovascular system.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Hyperplasia of the cardiac valves and outflow tract septation defects
indicate a function for Smad6 in the regulation of endocardial cushion
transformation.
explanation: >-
This directly supports an early morphogenetic node linking Smad6 loss to
valve and outflow tract defects.
evidence:
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
BMP signaling is required for normal heart valve and outflow tract development
[Goldman et al., 2009; Jiao et al., 2003; Liu et al., 2004; Ma et al.,
2005; Rivera-Feliciano and Tabin, 2006; Sugi et al., 2004; Zhang and
Bradley, 1996].
explanation: >-
This supports a core developmental dependency of the affected valve/outflow
tract tissues on BMP signaling.
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The level of BMP signaling is regulated by the inhibitory protein SMAD6,
which is highly expressed in the cardiac valves and outflow tract of the
embryonic heart and is upregulated by shear stress [Galvin et al., 2000;
Topper et al., 1997].
explanation: >-
This places SMAD6 directly in the embryonic cardiac valve and outflow
tract compartments relevant to disease.
- name: Congenital bicuspid valve and left-sided outflow phenotype
description: >-
The immediate structural phenotype is bicuspid aortic valve, often with
aortic stenosis and sometimes coarctation or related left-sided outflow
lesions.
downstream:
- target: Fibrocalcific valve degeneration and thoracic aortopathy
description: Congenital bicuspid architecture creates a substrate for later stenosis, calcification, and aneurysmal disease.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- altered hemodynamic shear stress
- persistent pro-osteogenic BMP signaling
evidence:
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
In vitro functional study of the p.Gly390_Ile391dup variant revealed impaired
inhibition of BMP signaling and BMP-induced alkaline phosphatase activity.
explanation: >-
This supports a mechanistic bridge from SMAD6 dysfunction to later
osteogenic/calcific degeneration in bicuspid valve disease.
evidence:
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The patient heterozygous for the p.C484F SMAD6 variant allele was found to
have a bicuspid aortic valve with mild aortic stenosis and aortic
coarctation at the age of 30 years
explanation: >-
This directly documents the congenital left-sided outflow phenotype in a
SMAD6-variant carrier.
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The other functionally significant SMAD6 variant we discovered (p.P415L)
was present in a patient who presented with a heart murmur at 18 months and
was found to have a bicuspid aortic valve with moderate aortic stenosis.
explanation: >-
A second independent SMAD6 variant supports the same congenital bicuspid
valve-aortic stenosis phenotype.
- name: Fibrocalcific valve degeneration and thoracic aortopathy
description: >-
Continued failure to restrain pro-osteogenic signaling, together with the
altered biomechanics of a bicuspid valve, promotes valve calcification,
stenosis progression, and associated thoracic aortic aneurysm.
evidence:
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Here, we identified novel in-frame variants in SMAD6
(c.1168_1173dup; p.Gly390_Ile391dup) in a BAV patient, who presented with
dilatation of the ascending aorta and severe calcification of the aortic valve.
explanation: >-
This case directly supports a downstream fibrocalcific and aneurysmal
disease node in SMAD6-related bicuspid valve disease.
- reference: PMID:25383261
reference_title: Periostin Expression is Altered in Aortic Valves in Smad6 Mutant Mice.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
Our immunohistochemical and immunointensity analyses revealed that
periostin expression was significantly reduced in the aortic valves in
Smad6-/- neonatal hearts.
explanation: >-
This supports altered aortic valve interstitial developmental programs in
Smad6-mutant tissue.
- reference: PMID:10655064
reference_title: A role for smad6 in development and homeostasis of the cardiovascular system.
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
The role of Smad6 in the homeostasis of the adult cardiovascular system is
indicated by the development of aortic ossification and elevated blood
pressure in viable mutants.
explanation: >-
This supports a later cardiovascular homeostasis failure and aortic
calcification branch downstream of Smad6 loss.
phenotypes:
- name: Bicuspid aortic valve
description: Congenital bicuspid aortic valve is the signature structural phenotype of this disease branch.
diagnostic: true
phenotype_term:
preferred_term: Bicuspid aortic valve
term:
id: HP:0001647
label: Bicuspid aortic valve
evidence:
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Both patients carrying functionally significant SMAD6 variants had bicuspid
aortic valves, the commonest cardiovascular malformation,
explanation: >-
This provides direct phenotype-level support for bicuspid aortic valve as
the defining lesion.
- name: Aortic valve stenosis
description: >-
Aortic valve stenosis occurs in SMAD6 variant carriers with bicuspid aortic
valve and can progress to clinically significant valve obstruction.
phenotype_term:
preferred_term: Aortic valve stenosis
term:
id: HP:0001650
label: Aortic valve stenosis
evidence:
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The patient heterozygous for the p.C484F SMAD6 variant allele was found to
have a bicuspid aortic valve with mild aortic stenosis and aortic
coarctation at the age of 30 years
explanation: >-
This directly documents aortic valve stenosis in a SMAD6 variant carrier
with the core bicuspid valve phenotype.
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The other functionally significant SMAD6 variant we discovered (p.P415L)
was present in a patient who presented with a heart murmur at 18 months and
was found to have a bicuspid aortic valve with moderate aortic stenosis.
explanation: >-
A second functionally significant SMAD6 variant supports aortic stenosis
as a recurrent phenotype in this cardiovascular branch.
- name: Aortic valve regurgitation
description: >-
Aortic regurgitation or insufficiency is part of the bicuspid aortic valve
clinical spectrum and should be monitored alongside stenosis because either
valve dysfunction pattern can determine timing of intervention.
phenotype_term:
preferred_term: Aortic regurgitation
term:
id: HP:0001659
label: Aortic regurgitation
evidence:
- reference: PMID:35867195
reference_title: "Bicuspid Aortic Valves: an Up-to-Date Review on Genetics, Natural History, and Management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It has a wide spectrum of clinical manifestations including aortic
regurgitation (AR), aortic stenosis, and an associated aortopathy with a
small but increased risk of aortic dissection.
explanation: >-
This review supports aortic regurgitation as part of the BAV phenotype
spectrum that must be monitored in SMAD6-related BAV/TAA.
- name: Thoracic aortic aneurysm
description: >-
Thoracic aortic aneurysm and ascending aortic dilatation are part of the
SMAD6-associated bicuspid valve-thoracic aortopathy spectrum.
phenotype_term:
preferred_term: Thoracic aortic aneurysm
term:
id: HP:0012727
label: Thoracic aortic aneurysm
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In conclusion, we report a significant contribution of SMAD6 mutations to
the etiology of the BAV/TAA phenotype.
explanation: >-
This cohort study directly links SMAD6 mutations to the combined bicuspid
aortic valve and thoracic aortic aneurysm phenotype.
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Here, we identified novel in-frame variants in SMAD6
(c.1168_1173dup; p.Gly390_Ile391dup) in a BAV patient, who presented with
dilatation of the ascending aorta and severe calcification of the aortic valve.
explanation: >-
This case report supports the thoracic aortopathy phenotype through
ascending aortic dilatation in a SMAD6-related BAV patient.
- name: Aortic dissection risk
description: >-
Aortic dissection is an uncommon but important complication of BAV-associated
aortopathy, especially when thoracic aortic dilation progresses without
surveillance or appropriately timed intervention.
phenotype_term:
preferred_term: Aortic dissection
term:
id: HP:0002647
label: Aortic dissection
frequency: OCCASIONAL
evidence:
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The risk of aortic dissection in BAV is 8.4 times higher than in the
general population (Michelena et al., 2011).
explanation: >-
This supports dissection risk as a clinically important downstream
complication of BAV-associated thoracic aortopathy.
- name: Coarctation of aorta
description: >-
Coarctation of aorta is a left-sided outflow-tract malformation reported in
SMAD6 variant carriers with bicuspid aortic valve.
phenotype_term:
preferred_term: Coarctation of aorta
term:
id: HP:0001680
label: Coarctation of aorta
evidence:
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The patient heterozygous for the p.C484F SMAD6 variant allele was found to
have a bicuspid aortic valve with mild aortic stenosis and aortic
coarctation at the age of 30 years
explanation: >-
This directly documents aortic coarctation in a SMAD6 variant carrier
with bicuspid aortic valve.
- name: Aortic valve calcification
description: >-
Severe aortic valve calcification can accompany the fibrocalcific phase of
SMAD6-related bicuspid aortic valve disease.
phenotype_term:
preferred_term: Aortic valve calcification
term:
id: HP:0001646
label: Abnormal aortic valve morphology
evidence:
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Here, we identified novel in-frame variants in SMAD6
(c.1168_1173dup; p.Gly390_Ile391dup) in a BAV patient, who presented with
dilatation of the ascending aorta and severe calcification of the aortic valve.
explanation: >-
HPO does not provide a specific aortic valve calcification term in the
local ontology; this evidence supports the more specific display term
under the closest available aortic valve morphology parent.
genetic:
- name: SMAD6
gene_term:
preferred_term: SMAD6
term:
id: hgnc:6772
label: SMAD6
association: Causative (Primary)
notes: >-
Heterozygous loss-of-function variants and deleterious missense changes in
the MH1/MH2 domains define the main molecular route. The cardiovascular
phenotype spans bicuspid aortic valve, aortic stenosis, coarctation, and
thoracic aortic aneurysm.
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SMAD6 was identified as the most important known gene in the etiology of
BAV with associated TAA.
explanation: >-
This large cohort establishes SMAD6 as the principal known gene for the
bicuspid valve-thoracic aneurysm phenotype captured here.
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We conclude that low-frequency deleterious variants in SMAD6 predispose to CVM.
explanation: >-
This original report establishes SMAD6 as a causal contributor to the
cardiovascular malformation branch.
variants:
- name: NM_005585.5(SMAD6):c.1451G>T (p.Cys484Phe)
description: >-
MH2-domain missense variant identified in a proband with bicuspid aortic
valve, aortic stenosis, coarctation, and heavy aortic arch calcification.
type: missense_variant
gene:
preferred_term: SMAD6
term:
id: hgnc:6772
label: SMAD6
evidence:
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The patient heterozygous for the p.C484F SMAD6 variant allele was found to
have a bicuspid aortic valve with mild aortic stenosis and aortic
coarctation at the age of 30 years
explanation: >-
This directly links the p.Cys484Phe variant to the core cardiovascular phenotype.
- name: NM_005585.5(SMAD6):c.1244C>T (p.Pro415Leu)
description: >-
MH2-domain missense variant identified in an infant with bicuspid aortic
valve and moderate aortic stenosis.
type: missense_variant
gene:
preferred_term: SMAD6
term:
id: hgnc:6772
label: SMAD6
evidence:
- reference: PMID:22275001
reference_title: Nonsynonymous variants in the SMAD6 gene predispose to congenital cardiovascular malformation.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The other functionally significant SMAD6 variant we discovered (p.P415L)
was present in a patient who presented with a heart murmur at 18 months and
was found to have a bicuspid aortic valve with moderate aortic stenosis.
explanation: >-
This provides a second representative disease-causing SMAD6 variant in
the aortic valve disease 2 branch.
diagnosis:
- name: Echocardiographic Valve Assessment
description: >-
Transthoracic echocardiography is the core diagnostic and surveillance test
for identifying bicuspid aortic valve, grading stenosis or regurgitation,
and measuring aortic root or ascending-aorta dimensions over time.
diagnosis_term:
preferred_term: echocardiography
term:
id: MAXO:0010203
label: echocardiography
evidence:
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A 42‐year‐old man visited Samsung Medical Center due to an ascending
aortic dilatation and echocardiography revealed BAV with severe
calcification of the aortic valve.
explanation: >-
This SMAD6-related BAV/TAA case directly supports echocardiography for
identifying the bicuspid valve and valve calcification.
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Aortic diameter dimensions were determined using echocardiography,
computed tomography or magnetic resonance imaging.
explanation: >-
This supports echocardiography as one of the core diagnostic modalities
for aortic measurements in BAV/TAA cohorts.
- name: Cross-Sectional Aortic Imaging
description: >-
CT angiography or MRI is used to define aortic-root and ascending-aorta
dimensions, detect thoracic aneurysm, and guide surveillance or surgical
timing when echocardiographic windows are insufficient or aortopathy is
present.
diagnosis_term:
preferred_term: computed tomography procedure
term:
id: MAXO:0000571
label: computed tomography procedure
evidence:
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
CT angiography of the aorta showed significant dilatation of the
ascending aorta (diameter: 5.5 cm) and dense calcification in the aortic
valve (Figure 1).
explanation: >-
This directly supports CT angiography for defining ascending-aorta
dilation in SMAD6-related BAV/TAA.
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Aortic diameter dimensions were determined using echocardiography,
computed tomography or magnetic resonance imaging.
explanation: >-
This supports cross-sectional imaging as part of BAV/TAA diagnostic
assessment and longitudinal aortic measurement.
- name: SMAD6 and BAV/Aortopathy Genetic Testing
description: >-
Molecular testing should evaluate SMAD6 and other BAV/aortopathy genes when
familial BAV/TAA, thoracic aneurysm, early valve calcification, or syndromic
features are present. Results should be interpreted with incomplete
penetrance and locus heterogeneity in mind.
diagnosis_term:
preferred_term: molecular genetic testing
term:
id: MAXO:0000533
label: molecular genetic testing
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We performed targeted resequencing of 22 candidate genes using Haloplex
target enrichment in a strictly defined BAV/TAA cohort
explanation: >-
This supports multigene BAV/TAA testing that includes SMAD6 and other
candidate aortopathy genes.
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We screened 20 genes known to be associated with BAV (Debiec et al.,
2017).
explanation: >-
This independent SMAD6-related case supports BAV/aortopathy gene-panel
testing in patients with calcified BAV and TAA.
- name: Family Screening and Cascade Evaluation
description: >-
First-degree relatives of SMAD6 variant carriers or familial BAV/TAA
probands should receive clinical cardiovascular screening and targeted
familial-variant testing when a pathogenic variant is known. Unaffected
carrier status does not exclude later thoracic aortopathy.
diagnosis_term:
preferred_term: genetic testing
term:
id: MAXO:0000127
label: genetic testing
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
When family members were available, Sanger sequencing of the SMAD6 variants
identified in the proband was performed in additional relatives to check if
the phenotype segregated with the variant.
explanation: >-
This directly supports cascade familial-variant testing after a SMAD6
variant is identified.
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A positive family history was defined as having at least one first- or
second-degree relative with BAV and/or TAA.
explanation: >-
This supports family-based cardiovascular screening around BAV/TAA.
treatments:
- name: Cardiovascular Surveillance and Risk-Factor Management
description: >-
Management requires longitudinal valve and aortic surveillance, monitoring
for stenosis or regurgitation progression, and individualized treatment of
modifiable cardiovascular risks such as hypertension. Surveillance intensity
should reflect valve dysfunction, aortic diameter, family history, and
growth rate.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:35867195
reference_title: "Bicuspid Aortic Valves: an Up-to-Date Review on Genetics, Natural History, and Management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The current knowledge regarding pathophysiologic mechanisms, screening,
and surveillance guidelines for BAV and the associated aortopathy is
discussed.
explanation: >-
This supports ongoing surveillance as a core management element for BAV
and associated aortopathy.
- reference: PMID:24332283
reference_title: Surgical thresholds for bicuspid aortic valve associated aortopathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Decision-making regarding the timing of intervention needs to be made on
the basis of the balance between this low risk and both the morbidity and
mortality of surgery.
explanation: >-
This supports individualized surveillance-based management before
intervention.
- name: Aortic Valve and Aortic Surgery
description: >-
Severe valve stenosis or regurgitation may require aortic valve repair or
replacement, and progressive aortic-root or ascending-aorta dilation may
require root or ascending-aorta repair. Surgical timing should be based on
imaging, symptoms, valve dysfunction, aortic size, and patient-specific risk.
treatment_term:
preferred_term: surgical procedure on cardiovascular system
term:
id: MAXO:0025001
label: surgical procedure on cardiovascular system
evidence:
- reference: PMID:35867195
reference_title: "Bicuspid Aortic Valves: an Up-to-Date Review on Genetics, Natural History, and Management."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We also discuss current management techniques for aortic valve repair
versus replacement, indications for aortic surgery (root or ascending
aorta), and the emergence of the Ross procedure as a viable management
option not only in children, but also in adolescents and adults.
explanation: >-
This supports valve repair/replacement and aortic surgery as major
interventions in BAV management.
- reference: PMID:24332283
reference_title: Surgical thresholds for bicuspid aortic valve associated aortopathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In asymptomatic patients, the timing of surgical management is based upon
imaging of aortic size, but the actual threshold is based upon
observational data and expert opinion.
explanation: >-
This supports imaging-based surgical timing for BAV-associated aortopathy.
- name: Genetic Counseling
description: >-
Genetic counseling should explain autosomal dominant inheritance, incomplete
penetrance, variable expressivity, possible unaffected carriers, family
screening, and the allelic relationship between the cardiovascular SMAD6
branch and SMAD6-associated craniosynostosis.
treatment_term:
preferred_term: genetic counseling
term:
id: MAXO:0000079
label: genetic counseling
evidence:
- reference: PMID:28659821
reference_title: "Candidate Gene Resequencing in a Large Bicuspid Aortic Valve-Associated Thoracic Aortic Aneurysm Cohort: SMAD6 as an Important Contributor."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Transmission of BAV/TAA mostly complies with an autosomal dominant inheritance
pattern, displaying reduced penetrance and variable expressivity
explanation: >-
This supports counseling about autosomal dominant inheritance with reduced
penetrance and variable expressivity.
- reference: PMID:30848080
reference_title: A novel SMAD6 variant in a patient with severely calcified bicuspid aortic valve and thoracic aortic aneurysm.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
SMAD6 is associated with not only BAV but also susceptibility of
craniosynostosis (Timberlake et al., 2016).
explanation: >-
This supports counseling that craniosynostosis is an allelic SMAD6
association rather than the primary scope of this cardiovascular entry.
references:
- reference: PMID:35867195
title: "Bicuspid Aortic Valves: an Up-to-Date Review on Genetics, Natural History, and Management."
findings: []
- reference: PMID:24332283
title: Surgical thresholds for bicuspid aortic valve associated aortopathy.
findings: []
notes: >-
This entry intentionally models the cardiovascular branch of SMAD6-related
disease rather than the broader ClinGen-lumped SMAD6 spectrum or the
craniosynostosis branch modeled in `SMAD6-related_Craniosynostosis.yaml`.
Craniosynostosis is therefore treated as an allelic SMAD6 association relevant
to counseling and differential scope, not as a defining feature of this
cardiovascular entry. The coherent pathograph after the shared BMP-signaling
trunk is centered on valve, outflow tract, and aortic developmental pathology.
Aortic Valve Disease 2 (AOVD2) is a Mendelian form of aortic valve disease characterized by a congenital bicuspid aortic valve (BAV) with associated ascending aortic aneurysm. Patients have two aortic valve leaflets instead of the normal three, predisposing them to valve dysfunction (stenosis or regurgitation) and aortopathy (www.malacards.org). The condition is caused by heterozygous loss-of-function mutations in the SMAD6 gene (HGNC:6772) on chromosome 15q22 (www.malacards.org). BAV is the most common congenital cardiac defect (prevalence ~0.5–2% of the population) and is increasingly recognized as a syndrome involving both the aortic valve and ascending aorta (pmc.ncbi.nlm.nih.gov). Most individuals with a BAV will develop valvular calcification, stenosis, and/or progressive aortic dilation over time (pmc.ncbi.nlm.nih.gov) (www.malacards.org). In AOVD2, the presence of a SMAD6 mutation establishes a clear genetic trigger that drives abnormal valve development and accelerates disease progression.
Developmental mechanisms: Normally, aortic valve formation during embryogenesis requires tightly regulated signaling between endothelial, neural crest, and mesenchymal cells. Endothelial cells in the outflow tract undergo endothelial-to-mesenchymal transition (EndMT) to form valve primordia (endocardial cushions), a process orchestrated by bone morphogenetic protein (BMP) and TGF-β signaling, along with NOTCH1 (HGNC:7881) signaling (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). SMAD6 encodes an inhibitory SMAD protein that is a critical negative regulator of the BMP/TGF-β pathway during heart development (pmc.ncbi.nlm.nih.gov). Under normal conditions, SMAD6 is highly expressed in the embryonic cardiac valves and outflow tract, as well as in the adult aortic root endothelium and smooth muscle (pmc.ncbi.nlm.nih.gov). SMAD6 protein restrains BMP/TGF-β signaling by binding BMP type I receptors or sequestering SMAD4, thereby preventing phosphorylation and nuclear translocation of SMAD1/5/8 mediators (pmc.ncbi.nlm.nih.gov). It also recruits ubiquitin ligases (SMURF1/2) to degrade BMP pathway receptors and effectors (pmc.ncbi.nlm.nih.gov). This negative feedback is crucial for proper valve morphogenesis and for maintaining vascular homeostasis (pmc.ncbi.nlm.nih.gov). Loss of SMAD6 function leads to unopposed BMP/TGF-β signaling during valve formation, which perturbs normal cusp development. Indeed, mice lacking SMAD6 (Madh6^–/–) exhibit valvular thickening, outflow tract septation defects, and ectopic ossification of the cardiac outflow tract (pmc.ncbi.nlm.nih.gov), reflecting the consequences of excess BMP activity in development. In humans, two missense SMAD6 variants in the BMP-interacting MH2 domain were first identified in BAV patients with congenital aortic stenosis (pmc.ncbi.nlm.nih.gov), supporting that SMAD6 dysfunction in utero can produce a BAV anatomy (typically a fused leaflet).
Bicuspid valve architecture from SMAD6 mutations sets the stage for disease by altering valve biomechanics and signaling. A BAV creates eccentric, turbulent flow through the aortic valve, which results in abnormal shear stress on the valve leaflets and ascending aorta. Endothelial cells on the aortic side of BAV leaflets experience low, oscillatory shear, leading to localized endothelial dysfunction. This disturbed flow induces pro-osteogenic and pro-fibrotic mediators in the valve. For example, endothelial cells under low shear produce BMP4, a potent osteogenic factor that can trigger underlying interstitial cells to undergo osteoblastic differentiation (www.nature.com). In parallel, loss of SMAD6 means there is reduced intrinsic brake on BMP signaling in these cells. NOTCH1, another gene implicated in familial BAV, normally cross-talks with BMP/TGF-β pathways to modulate valve development and calcification (pmc.ncbi.nlm.nih.gov). NOTCH1 signaling maintains valvular interstitial cells (VICs) in a quiescent, non-osteogenic state in part by upregulating factors (e.g. HEY transcription factors) that suppress osteoblast gene programs. NOTCH1 haploinsufficiency (the cause of Aortic Valve Disease 1) removes this restraint and has been shown to promote early calcific aortic valve disease via upregulation of RUNX2 and BMP2 signaling (pmc.ncbi.nlm.nih.gov). Thus, both SMAD6 and NOTCH1 mutations converge on dysregulated osteogenic signaling in the valve, although via different mechanisms (loss of a BMP inhibitor vs. loss of a Notch activator).
SMAD6–BMP/TGF-β Pathway: AOVD2 is fundamentally a disease of enhanced BMP/TGF-β signaling. SMAD6 normally serves as a checkpoint to prevent excessive pro-osteogenic signaling. “SMAD6 encodes an inhibitory SMAD protein which negatively regulates BMP signaling by binding to BMP type I receptors or by establishing competitive interactions for SMAD4” (pmc.ncbi.nlm.nih.gov), thereby preventing phosphorylation of SMAD1/5/8. In the absence of sufficient SMAD6 function, BMP pathway signaling is hyperactivated. Patient-derived studies demonstrate that mutant SMAD6 proteins have impaired ability to inhibit BMP signals, leading to greater downstream SMAD1/5/8 phosphorylation and gene activation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In a functional analysis, Park et al. (2019) showed a SMAD6 mutant (p.Gly390_Ile391dup) failed to suppress BMP2-induced transcriptional activity and lost the ability to inhibit osteogenic differentiation in vitro (pmc.ncbi.nlm.nih.gov). Specifically, wild-type SMAD6 could block alkaline phosphatase activity (an osteoblast marker) in a BMP-stimulated cell culture, but the SMAD6 mutants could not, “suggesting that the mutant protein had less efficacy in preventing tissue calcification” (pmc.ncbi.nlm.nih.gov). Consequently, VICs and other mesenchymal cells in the valve are biased toward an osteogenic fate. Excess BMP signaling also affects valve precursor cells: it promotes premature calcification and alters cushion remodeling. If BMP signals are not properly counter-balanced (as in SMAD6 mutation), valve cusps may fuse or develop abnormally, yielding the bicuspid morphology (pmc.ncbi.nlm.nih.gov). Additionally, SMAD6 has some capacity to directly modulate TGF-β signaling (it can bind type I TGF-β receptors as well), so its loss may also increase TGF-β activity (pmc.ncbi.nlm.nih.gov). Heightened TGF-β signaling in the aortic valve and root can drive fibrogenesis and extracellular matrix (ECM) remodeling, compounding the stiffening of the valve. Notably, many genes causing ascending aortic aneurysms (e.g. TGFBR1/2, SMAD3 in Loeys-Dietz syndrome) lead to excess TGF-β signaling (pmc.ncbi.nlm.nih.gov), and the SMAD6 pathway links into this same network. The net effect of SMAD6 dysfunction is a persistent pro-osteogenic, pro-fibrotic milieu in the valve and aorta.
NOTCH1 and other genetic factors: Several other genes contribute to valve development and disease, underscoring the complex genetic architecture. NOTCH1 (HGNC:7881) is the most well-established, with heterozygous NOTCH1 mutations known to cause BAV and early calcific aortic stenosis in some families (pmc.ncbi.nlm.nih.gov). NOTCH1 signaling normally inhibits osteoblastic gene programs in VICs (partly by suppressing BMP2 and Runx2), so Notch1 loss leads to calcific nodule formation in the valve cusps (pmc.ncbi.nlm.nih.gov). “NOTCH1, SMAD6, and GATA5 are associated with BAV in humans, but few cases have been reported that did not involve NOTCH1” (pmc.ncbi.nlm.nih.gov) – highlighting that NOTCH1 was the predominant known monogenic cause until SMAD6 and others were identified. GATA5 (HGNC:15802), a developmental transcription factor, was reported in a few BAV cases and is implicated by mouse models (Gata5 knockout mice develop BAV), though human mutations are rare (pmc.ncbi.nlm.nih.gov). More recently, exome sequencing in BAV cohorts has uncovered novel contributors like ROBO4 (HGNC:13485), an endothelial guidance receptor: pathogenic ROBO4 variants segregated with BAV, aortic valve stenosis (AVS), and aortopathy in some families (pmc.ncbi.nlm.nih.gov). These genes converge on pathways governing valvulogenesis, ECM organization, and cell differentiation. The emerging picture is that BAV and related aortic disease have a polygenic basis in most cases (www.nature.com). Even in sporadic calcific aortic valve disease (CAVD), genome-wide studies show risk loci in genes related to lipid metabolism, inflammation, and calcification (www.nature.com) (for example, variants in the IL6 gene and in the bone mineralization enzyme gene ALPL were associated with calcific AS (www.nature.com)). Thus, SMAD6 is one key player in a larger network of genetic factors. In AOVD2 specifically, the SMAD6 mutation is the primary driver, but other modifiers (hypertension, diabetes, additional gene variants) can influence the severity of outcomes in individual patients (www.nature.com).
Cellular players and affected tissues: The pathophysiology spans multiple cell types and anatomical locations. The primary cells involved are the valve interstitial cells (VICs) within the aortic valve leaflets. VICs (deriving from cushion mesenchyme, including neural crest and EndMT-derived cells) normally remain quiescent and help maintain the valve ECM. In diseased valves, VICs become activated to a myofibroblast-like phenotype and can further differentiate into osteoblast-like cells. These osteogenic VICs begin expressing bone matrix proteins (like osteopontin, osteocalcin) and the master bone transcription factor RUNX2, recapitulating a bone formation program (www.nature.com). Histologically, calcified valves contain areas of true bone tissue – calcium hydroxyapatite deposition organized by these cells, confirming that “human aortic valve calcification is associated with an osteoblast phenotype” (www.nature.com). Valve endothelial cells are another important cell type: they line the surface of the leaflets and in BAV they exhibit region-specific responses to abnormal flow. Endothelial cells on the lesser-shear side (aortic side) upregulate adhesion molecules and osteogenic cytokines (e.g. BMP4, ICAM-1), promoting inflammation and calcification in the underlying tissue (www.nature.com). Periodically, endothelial cells can also undergo a pathological EndMT in adult valves, contributing new mesenchymal cells that amplify fibrosis and calcification in response to injury or inflammation.
The ascending aortic wall is also directly affected in AOVD2. The aorta contains vascular smooth muscle cells (SMCs) in the medial layer that express SMAD6 and are influenced by TGF-β/BMP signaling. Loss of SMAD6 in these cells may lead to abnormal SMC behavior and matrix remodeling in the aortic media. Indeed, SMAD6 is expressed in the aortic root SMCs and adult endothelium, and SMAD6-mutant mice show vascular smooth muscle dysfunction and hyperplasia (pmc.ncbi.nlm.nih.gov). In patients, a dilated ascending aorta (aneurysm) is a hallmark of AOVD2 (www.malacards.org). The aortic dilation is thought to result from both genetic factors (intrinsic weakness of the connective tissue due to dysregulated TGF-β signaling) and hemodynamic factors (high velocity jet flow through a BAV causing wall stress). Excess TGF-β signaling in the aorta can increase expression of matrix metalloproteinases and other proteolytic enzymes that degrade elastin and collagen in the media, leading to loss of aortic wall integrity (pmc.ncbi.nlm.nih.gov). Many syndromic aneurysm conditions (Marfan, Loeys-Dietz) share this final common pathway of elastin fragmentation and medial degeneration due to TGF-β pathway overactivity (pmc.ncbi.nlm.nih.gov). In AOVD2, although not as dramatic as Loeys-Dietz, a similar mechanism likely contributes to slow expansion of the ascending aorta. Inflammatory cells also play a role: macrophages and T lymphocytes infiltrate calcifying valves and aortic tissue. Macrophages release pro-inflammatory cytokines like TNF-α, which “promotes an osteoblast-like mechanism of valvular calcification” (www.nature.com) by accelerating VIC osteogenic differentiation. They also secrete IL-1β and IL-6, driving chronic inflammation and fibrosis in the valve. These inflammatory pathways create a feed-forward loop (inflammation stimulates calcification, which in turn attracts more inflammatory cells). Notably, valve lesions from BAV patients show higher inflammation and angiogenesis compared to tricuspid valves (www.nature.com), indicating a more aggressive disease process.
Several biological processes are perturbed in AOVD2 due to SMAD6 mutation and BAV anatomy:
Heart valve morphogenesis (GO:0003170) – The developmental program of aortic valve formation is disrupted. SMAD6-related BMP overactivity alters cushion formation, leaflet separation, and cusp patterning, leading to a bicuspid valve instead of the normal trileaflet structure (pmc.ncbi.nlm.nih.gov). This involves aberrant endothelial to mesenchymal transition in the outflow tract and misregulated neural crest cell migration into the aortic valve region (pmc.ncbi.nlm.nih.gov).
BMP signaling pathway (GO:0030510) – Normally tightly controlled, this pathway is hyperactivated. Loss of negative regulation by SMAD6 means increased phosphorylation of Smad1/5/8 and transcription of BMP target genes in valve and aortic cells (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The result is enhanced expression of osteogenic and chondrogenic genes that drive calcification. There is also evidence for crosstalk where excessive BMP signaling can amplify TGF-β signals and vice-versa (pmc.ncbi.nlm.nih.gov), compounding the effect on tissue remodeling.
Negative regulation of ossification (GO:0030279) – This braking process is impaired. In healthy valves, signaling pathways (Notch, SMAD6, etc.) actively suppress ectopic bone formation. In AOVD2, the inability to properly inhibit osteogenic transcription programs leads to inappropriate bone mineralization in the valve (ectopic ossification) (pmc.ncbi.nlm.nih.gov). Genes like RUNX2 (normally low in valves) become upregulated, and VICs transition to osteoblast-like cells producing calcium hydroxyapatite deposits (www.nature.com).
Extracellular matrix organization (GO:0030198) – Valvular and aortic ECM homeostasis is altered. Both fibrosis (excess collagen, proteoglycan deposition) and matrix degradation occur. Early in disease, valvular interstitial cells secrete more collagens and proteoglycans, causing cusp thickening (fibrosis/sclerosis). Later, regions of the valve and aortic wall undergo proteolysis: matrix metalloproteinases are upregulated by TGF-β and inflammatory cytokines, leading to elastin fragmentation in the aortic media and facilitating calcific nodule eruption in valve tissue. These changes correspond to a transition from a flexible, compliant valve to a stiff, fibrotic, and calcified structure (www.nature.com) (www.nature.com).
Inflammatory response (GO:0006954) – Chronic inflammation is a key part of the pathogenesis. Endothelial injury and lipid deposition in the valve leaflets trigger an immune response akin to atherosclerosis. Monocyte/macrophage infiltration occurs in early lesion development, and their cytokines (TNF-α, IL-1, IL-18) promote VIC differentiation into osteoclast-like and osteoblast-like cells (www.nature.com) (www.nature.com). There is also evidence of oxidative stress and foam cell formation in calcific valves, linking lipid metabolism to inflammation (high LDL and lipoprotein(a) levels are risk factors for more rapid calcification (www.nature.com)). These biological processes – inflammation, lipid oxidation, and calcification – reinforce each other in disease progression.
Blood flow and shear stress mechanotransduction – Although not a classical GO term, the process by which cells sense and respond to mechanical shear is crucial here. Disturbed flow in BAV leads to endothelial cells switching to a pro-osteogenic phenotype via mechanosensitive pathways (involving KLF2, NOTCH, and BMP signaling) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Normally, laminar shear stress upregulates protective genes like KLF2 and SMAD6 itself (SMAD6 expression is induced by steady laminar flow) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In regions of disrupted flow, this mechanotransduction is altered: SMAD6 upregulation by shear is insufficient, and instead BMP4 and inflammation-related genes dominate, promoting calcification.
Pathological changes in AOVD2 span multiple cellular compartments:
Valve leaflet extracellular matrix (ECM): This is where calcific nodules form. The ECM of the aortic valve (especially the fibrosa layer on the aortic side) becomes a site of calcium phosphate deposition. Collagen fibers thicken and fragment around these calcific deposits. Glycosaminoglycan-rich areas (normally providing flexibility) may turn into fibrocalcific scar tissue. In advanced disease, bone tissue – including osteocytes and marrow-like elements – can be identified within the valve ECM (www.nature.com). The term aortic sclerosis refers to early ECM changes (collagen thickening) without significant obstruction (www.malacards.org), whereas calcific stenosis implies large calcified masses stiffening the ECM and reducing leaflet mobility.
Subcellular signaling domains: The plasma membrane of cells is where BMP/TGF-β receptors (e.g. BMPR1A, TGFBR2) are activated. In the absence of SMAD6, receptor signaling complexes at the membrane remain active longer, phosphorylating SMAD1/5/8. The cytoplasm is where SMAD6 normally sequesters these phosphorylated Smads and recruits ubiquitin ligases (SMURF1/2) to degrade receptor complexes (pmc.ncbi.nlm.nih.gov). With mutant SMAD6, more SMAD1/5/8 translocate to the nucleus, altering gene transcription. The nucleus of VICs then accumulates osteogenic transcription factors (RUNX2, OSX) and drives expression of bone matrix proteins. Meanwhile, in the nucleus of endothelial cells, disturbed-flow signaling alters the activity of transcription factors (like NF-κB, KLF2) that govern inflammation and BMP expression.
Valvular endothelium and intercellular junctions: Endothelial cell junctions on the aortic side of BAV leaflets often become disrupted due to turbulent flow. This allows enhanced paracellular permeability, so that lipids (e.g. LDL, Lp(a)) and inflammatory cells infiltrate the leaflet. These endothelial surfaces can also form micro-aggregates of platelets and fibrin, especially once sclerosis has begun – indeed, evidence of microthrombi and intraleaflet hemorrhages are found in diseased BAVs and correlate with rapid disease progression (www.nature.com).
Aortic wall architecture: In the ascending aorta, the tunica media (muscular middle layer) is the primary site of pathology. Normally, this layer has alternating elastic lamellae and SMC layers. In BAV-associated aortopathy (including AOVD2), there is medial degeneration: loss of SMCs, fragmentation of elastic fibers, and deposition of proteoglycan ground substance. Microscopic examination reveals areas of elastin breaks and fibrosis in the media, sometimes with focal inflammatory cell infiltrates. The adventitia (outer layer) may show vasa vasorum proliferation and inflammation in advanced aneurysms. From a molecular perspective, the extracellular space of the media sees imbalanced enzyme activity – e.g., elevated matrix metalloproteinase-2 and -9 (MMP2/9) and reduced TIMP (tissue inhibitor of MMPs), partly driven by TGF-β signaling. This environment leads to weakening and dilation of the aortic wall.
Calcific deposits: The extracellular calcium deposits in valves and aorta are primarily composed of hydroxyapatite (the same mineral found in bone) (www.nature.com). These deposits often form on collagen scaffolds in areas of low shear stress. In valves, calcific deposits start as microscopic microcalcifications that coalesce into larger nodules. Interestingly, the regions around calcific nodules often have evidence of apoptosis and cell debris, suggesting that VIC death (perhaps via a TNF-related apoptosis mechanism (www.nature.com)) contributes to calcific core formation by releasing calcium-rich vesicles. In the aorta, calcification is usually less pronounced than in the valve, but patches of medial calcification can occur (especially in aging or in presence of risk factors like chronic kidney disease).
Initial trigger (genetic and developmental stage): The cascade begins with the germline SMAD6 mutation (typically autosomal dominant with incomplete penetrance (pmc.ncbi.nlm.nih.gov)). During embryonic heart development, this molecular defect leads to malformed valve anatomy – usually a BAV, often of the fusion type (two cusps fused into one larger leaflet). In some cases, the developmental impact extends to adjacent structures: for example, a minority of SMAD6 mutation carriers have a coarctation of the aorta (a congenital narrowing of the aortic arch) (www.malacards.org), or other outflow tract anomalies, indicating perturbation of neural crest contributions to the great vessels. In utero, if the aortic valve or outflow is severely narrowed, it can even impair left ventricular development; “in extreme cases restricted blood flow can prevent left ventricle growth, resulting in hypoplastic left heart syndrome” (www.malacards.org), though this is a rare outcome. Generally, individuals with AOVD2 are born with a structurally abnormal valve but may be asymptomatic in infancy if the BAV is functioning with only mild stenosis or regurgitation.
Latent/compensated phase: Through childhood and young adulthood, the bicuspid valve often functions adequately. The heart compensates for any mild valve dysfunction. During this time, however, the seeds of pathology are present: the BAV’s abnormal hemodynamics cause regions of stress and altered signaling within the valve and aortic wall. By the second to third decade of life, histological changes of aortic sclerosis (valve leaflet thickening due to fibrosis) can typically be found (www.malacards.org). The ascending aorta may also begin to show mild dilation. Patients are often asymptomatic in this phase, though a BAV murmur can be detected clinically. Importantly, this is when preventive measures could be impactful – for instance, controlling blood pressure to reduce aortic wall stress, and managing lipids and inflammation to slow valve degeneration (www.nature.com). (Elevated lipoprotein(a), LDL cholesterol, and hypertension are known to accelerate calcific aortic stenosis, even in BAV patients (www.nature.com).) There is currently no approved medication to reverse or halt early calcific changes, but ongoing research is examining interventions like PCSK9 inhibitors (to aggressively lower lipids) and anti-inflammatory therapies to see if they can delay disease in this stage (www.nature.com).
Progressive disease phase: By mid-adulthood (40s–50s), many patients with AOVD2 enter a phase of accelerating valve calcification and aortic enlargement. Mechanistically, chronic endothelial injury and VIC activation lead to the formation of larger calcific nodules on the valve. What began as microscale calcium deposits expand and eventually coalesce, causing leaflet stiffening. The valve orifice area gradually narrows, and transvalvular blood flow becomes obstructed – this marks the onset of calcific aortic stenosis (AS). Clinically, valve gradients increase and patients may develop symptoms (exertional dyspnea, chest pain, syncope) once AS is severe. The stages of valvular disease can be described from Aortic sclerosis (mild thickening, no significant gradient) → Mild AS (small calcific nodules, mild gradient) → Moderate AS (more extensive calcification, moderate gradient) → Severe AS (heavy calcification with greatly reduced valve area). Pathologically, severe AS valves show rigid calcified cusps that may even be immobile. In BAV, calcification often localizes along the fusion raphe and cusp base. During this same period, the ascending aorta dilation often worsens. Many BAV/TAA patients show a steady aortic growth rate of perhaps 0.2–1.0 mm/year, but some SMAD6 mutation carriers might have a more rapid expansion (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). By the time the aorta diameter exceeds ~45–50 mm, the risk of catastrophic complications (aortic dissection or rupture) increases. Indeed, individuals with BAV have an estimated 8-fold higher risk of aortic dissection compared to the general population (pmc.ncbi.nlm.nih.gov). This risk underlies guidelines recommending prophylactic surgical repair of the aneurysm at a threshold (often ~5.0 cm for most BAV patients, potentially a bit lower if the growth rate is rapid or family history of dissection).
Late/advanced stage: In the absence of intervention, end-stage disease is characterized by severe calcific AS and possible heart failure, and/or extensive aortic aneurysm. The left ventricle may hypertrophy dramatically in response to chronic outflow obstruction, and eventually decompensate (leading to systolic dysfunction or heart failure). Severe valve stenosis also puts patients at risk for sudden cardiac death, especially upon exertion. Additionally, aortic dissection is a feared late complication if the aneurysm is untreated – a tear in the dilated ascending aorta can be life-threatening. Another complication in advanced disease is infective endocarditis on the abnormal valve. BAV patients have a higher lifetime risk of endocarditis than those with normal valves, because the abnormal flow and fibrotic surface promote bacterial adhesion. Endocarditis can further damage the valve or cause abscesses, compounding heart failure risk. Without surgical correction, these late-stage issues significantly reduce survival. In one series, untreated symptomatic severe BAV stenosis had a high 5-year mortality, and significant aortic aneurysms carry their own risk of fatal rupture. Fortunately, interventions can alter this course: surgical or transcatheter aortic valve replacement (AVR/TAVR) can effectively treat the stenosis, and aortic graft surgery can eliminate the aneurysm risk. Thus, the late stage is often preempted by surgery in modern practice.
AOVD2 manifests with a spectrum of clinical phenotypes that directly reflect its molecular and structural pathology:
Bicuspid Aortic Valve (HP:0001647) – The cardinal phenotype is the bicuspid valve itself. On imaging (echocardiogram or MRI), a BAV typically presents with two unequal-sized cusps and a fibrous raphe. Functionally, many BAVs are stenotic or regurgitant to some degree. The BAV is often discovered incidentally via a heart murmur in youth. This congenital phenotype results from the developmental mechanisms described (SMAD6-mediated signaling errors). Familial clustering of BAV is well-documented (www.nature.com); first-degree relatives of a BAV patient have a higher chance of also having BAV, consistent with heritable mutations like SMAD6 or NOTCH1 in some families (www.nature.com).
Aortic Valve Calcification and Stenosis (HP:0002758, HP:0001650) – Progressive calcific aortic stenosis is a major phenotype in mid-to-late life. The valve leaflets become visibly calcified on imaging (echo or CT) and motion is restricted. Clinically this corresponds to a harsh systolic murmur, rising transvalvular pressure gradients, and symptoms of aortic stenosis (exertional chest pain, fainting, shortness of breath). The underlying mechanism is the VIC osteogenic transformation and calcium deposition driven by BMP/TGF signaling and inflammation. Histopathology of stenotic BAVs shows nodular calcific masses, inflammatory infiltrates, and new blood vessel formation within the leaflets (www.nature.com). The severity of calcification correlates with SMAD6 dysfunction extent: for instance, the reported SMAD6 variant carriers often had “severely calcified bicuspid aortic valve” requiring surgery in their 40s-50s (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
Aortic Regurgitation (HP:0001659) – Some BAV patients (including AOVD2 cases) predominantly develop valve leaking rather than stenosis. Regurgitation can occur due to the uneven cusps failing to coapt tightly, or from prolapse of a fused cusp. Additionally, dilation of the ascending aorta can cause the annulus to stretch, worsening regurgitation. Clinically, significant aortic regurgitation leads to a bounding pulse and heart failure symptoms if severe. While calcification tends to cause stenosis, a myxomatous degeneration or fibrosis of cusps without calcification can cause regurgitation in some BAV individuals.
Ascending Aortic Aneurysm (HP:0002616) – Enlargement of the ascending aorta is a key phenotype in AOVD2. Patients often have gradual dilation of the aortic root or tubular ascending aorta. By MRI or CT, the aortic diameter may increase into the aneurysmal range (>40 mm, often 45–50+ mm if unchecked). This is directly linked to the underlying connective tissue changes from altered SMAD6/TGF-β signaling and the hemodynamic stress of BAV. The phenotype may be described as “BAV-associated aortopathy,” and it can present even when valve function is normal. In AOVD2 kindreds, some mutation carriers have required prophylactic aortic surgery due to aneurysm, even if their valve was only mildly diseased (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The risk of acute Aortic dissection (HP:0002647) is elevated as noted – a life-threatening tear often precipitated by an underlying aneurysm. Recognition of this risk has led to screening of relatives and early surgical intervention in familial cases.
Coarctation of Aorta (HP:0001680) – An occasional phenotype in AOVD2 is a coarctation (narrowing) of the descending aorta just distal to the subclavian artery. This was reported in at least one SMAD6 mutation carrier who had BAV and aortic aneurysm (pmc.ncbi.nlm.nih.gov). Coarctation is developmentally related to neural crest cell migration issues, suggesting a severe perturbation of outflow tract patterning in that case (likely due to the same SMAD6-driven embryologic derangements). Clinically, coarctation presents in childhood with upper-body hypertension and weak lower extremity pulses, often requiring surgical repair early in life. Its presence alongside BAV (the well-known “Shone’s complex” association) further indicates a developmental link.
Cardiac symptoms and complications: As the disease progresses, patients may experience angina (chest pain due to increased myocardial oxygen demand from LV hypertrophy), syncope (fainting, especially during exertion, from fixed cardiac output in severe AS), and heart failure (due to pressure overload or volume overload from regurgitation). These clinical manifestations are late phenotypic outcomes of the long-standing mechanical burden on the heart. Additionally, as mentioned, infective endocarditis (HP:0002751) is a concern – BAV is an independent risk factor for endocarditis (www.nature.com). Endocarditis can present with fever and valve vegetations; if it occurs on a calcified BAV, it often necessitates urgent valve replacement.
In summary, Aortic Valve Disease 2 (BAV with SMAD6 mutation) presents a clear example of how a genetic defect in a signaling regulator leads to altered developmental anatomy and a cascade of pathological processes. The primary pathophysiological mechanism is the loss of SMAD6’s inhibition of BMP/TGF-β signaling, which causes a bicuspid valve to form and sets off valve tissue degeneration via osteogenic and inflammatory pathways. Key molecular players include SMAD6 itself, the BMP2/4–SMAD1/5/8 axis, the NOTCH1–Hey axis, pro-osteogenic factors like RUNX2, and inflammatory mediators (TNF-α, IL-6, etc.), all acting on crucial cell types (valve interstitial cells, endothelium, smooth muscle). The disease progresses from a congenital anomaly to fibro-calcific valvular disease and aortic aneurysm, typically over decades, with distinct stages from subclinical thickening to overt stenosis and dilation. The clinical phenotypes – BAV morphology, calcific aortic stenosis, and aneurysm/dissection – can be directly tied to these underlying mechanisms. Research continues to explore targeted therapies (for example, trials of agents like evogliptin (a DPP-4 inhibitor) to slow calcification (www.malacards.org), and lipoprotein(a)-lowering drugs to reduce lipid-driven valve mineralization) with the hope of interrupting the disease process before end-stage surgery is required. For now, management relies on surveillance and timely surgical intervention. This marriage of developmental biology, molecular signaling, and clinical cardiology in AOVD2 exemplifies the complex pathophysiology of valvular heart disease and highlights the importance of pathways like BMP/TGF-β in cardiovascular health (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).
Evidence: The link between SMAD6 mutations and BAV with aortopathy has been established by human genetic studies and experimental models. Rare SMAD6 variants were found in ~2.5% of patients with BAV and thoracic aortic aneurysm, a significant enrichment over controls (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). “We identified 11 SMAD6 variants in 441 BAV/TAA patients (2.5%).… All six missense mutations were located in the functionally important MH1 and MH2 domains” (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Familial segregation analyses and animal models support a causal role: SMAD6 knockout mice recapitulate key aspects (valve thickening, OFT ossification) (pmc.ncbi.nlm.nih.gov), and human carriers show the expected phenotype spectrum (BAV, early calcification, aneurysm) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This body of evidence, from molecular assays (demonstrating loss of BMP inhibition) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) to clinical observations (aggressive calcification in SMAD6-mutant BAV valves) (pmc.ncbi.nlm.nih.gov), provides a robust understanding of AOVD2 pathophysiology. As noted by one expert review, “Bicuspid aortic valve is increasingly recognized as a disorder of both the valve and the aorta, with genetic mutations like NOTCH1 and SMAD6 underpinning early valve degeneration and aortic malformations” (www.frontiersin.org) (pmc.ncbi.nlm.nih.gov). Continued research in this area (including single-cell genomics of valve tissue (www.nature.com) and mechanistic studies of SMAD6 in vascular cells (pmc.ncbi.nlm.nih.gov)) is expected to yield further insights, potentially guiding novel therapies to modulate these molecular pathways in AOVD2 and related valvular diseases.
References: (Key citations supporting the above content)
Each of these sources supports the link between molecular dysregulation (SMAD6/BMP/TGF-β, NOTCH1) and the cellular pathology (valve calcification, aortopathy) observed in Aortic Valve Disease 2. The convergence of developmental biology and adult disease mechanisms in this condition makes it a prototypical example of cardiovascular pathophysiology influenced by genetic mutations. All evidence underscores that excess osteogenic signaling and impaired inhibitory feedback in valvular cells are central to the disease, driving the progression from a bicuspid valve at birth to calcific aortic stenosis and aneurysm in later life (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The detailed understanding of these pathways offers hope that future targeted therapies (for example, BMP/TGF-β pathway modulators, or anti-calcification treatments) could ameliorate or prevent the grave outcomes of AOVD2.